Abstract
Background The cardiovascular-kidney-metabolic (CKM) syndrome is a newly defined chronic health condition from American Heart Association. We assessed the prevalence of CKM syndrome stages 0-2, which have not yet progressed to cardiovascular disease (stage 3-4) with trends analysis over the past two decades.
Methods We used cross-sectional data provided by National Health and Nutrition Examination Survey. including non-pregnant participants aged 18 or older between 1999 and 2020. Weighted prevalence was analyzed over the course of the past 20 years and by population subgroup (including age, sex, and race/ethnicity).
Results A total of 32848 US adults were included in our study (weighted mean age, 47.3 years; women, 51.3%). 7.9% of US adults were at stage 0 without any CKM risk factors, with 64% of this subgroup being female. 18.3% of US adults were classified as stage 1 with issues related to excess or dysfunctional adiposity without other metabolic risk factors or chronic kidney disease (CKD). More than half of the US adults (56.5%) exhibited either metabolic risk factors, CKD, or both (stage 2). Between 1999 and 2020, the CKM features increased with decreasing prevalence of stage 0 (P for trends =0.0018), not only in females but also in males.
Conclusions Our findings illustrate an exceptionally high and increasing prevalence of CKM syndrome among US adults. This emphasizes the importance of comprehensive preventive strategies targeting the life style of large parts of the population. Moreover, further risk assessment should be implemented into stage 2 cohort to define patients with exceptional cardiovascular risk.
What is new?
CKM syndrome is a common chronic health condition in the general population. However, the prevalence of different CKM stages using real-world data has not been reported within the general population or its subgroups.
The prevalence of CKM syndrome was increasing over the past two decades. The majority of US adults were classified as stage 2.
A specific population remained undefined according to the current detailed definition of each CKM syndrome stage.
What are the clinical implications?
The high and increasing prevalence of CKM syndrome necessitates more precise preventive strategies, tailored to different target groups with consideration of age-, sex-, and gender-disparities.
Given that approximately half of the study population fell into stage 2 with a wide spectrum of risk factors, it is imperative to identify patients with exceptionally high risk through additional risk assessments. This approach would facilitate the implementation of intensified treatment measures aimed at preventing the progression to cardiovascular disease (CKM syndrome stages 3-4).
Competing Interest Statement
SS received honoraria from AstraZeneca for lectures and consulting and from KelCon for lectures, not related to this article.. JB received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, Norgine, Edwards, Roche not related to this article; and research support for the department from Zoll, CVRx, Abiomed, Norgine, Roche, not related to this article. KSO received lecture fees and honoraria from Boehringer Ingelheim, Astrazeneca, Bayer, Vifor, Alexion, Novartis, BioPorto Diagnostics and Abionyx, not related to this article. BMWS received lecture fees and honoraria from ADVITOS, Amgen, Bayer Vital, Berlin Chemie-Menarini, CytoSorbents, Daichii Sankyo, Miltenyi, Pocard, not related to this article.
Clinical Trial
this is not a clinical trial.
Funding Statement
There is no funding source in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study procedures are approved by the National Center for Health Statistics Research Ethics Review Board. The Hannover Medical School Institutional Review Board exempted the present study due to deidentified data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
NHANES data are available from the NHANES web page. The R code of the analysis is available from the authors on reasonable request.
Abbreviations and Acronyms
- BMI
- Body mass index
- CKD
- Chronic kidney disease
- CKM
- syndrome Cardiovascular-kidney-metabolic syndrome
- CVD
- Cardiovascular disease
- eGFR
- Estimated glomerular filtration rate
- MetS
- Metabolic syndrome
- NHANES
- National Health and Nutrition Examination Survey
- UACR
- Urinary albumin to creatinine ratio
